TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33917916
Drug: 6 week
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 week low-dose combined resistance and endurance training program (TG)
Study: 34373362
Drug: Sodium alginate
Normalized name: Sodium Alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium alginate (orally administered for 3 days after EGD)
Study: 36138465
Drug: Protocolized fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized fluid removal with an UFNET rate set to 0‐25 ml h‐1 between inclusion and H72 of inclusion.
Study: 32907500
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg donafenib twice daily for 24 weeks
Study: 36153518
Drug: Fruit and
Normalized name: elderberry fruit and flower 460 mg-115 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit and Vegetable Intervention Arm (weekly counseling and supplemental fruit and vegetable box delivery for 20 weeks)
Study: 32897570
Drug: Aprocitentan 10
Normalized name: Aprocitentan
DrugBank: Aprocitentan (DB15059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprocitentan 10 mg/day for 9 days
Study: 35684031
Drug: Syrup
Normalized name: Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup
Study: 33814231
Drug: Peak anti-HBs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak anti-HBs levels in 100–1000 mIU/mL or ≥ 1000 mIU/mL
Study: 32109194
Drug: Cladribine monotherapy
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine monotherapy
Study: 38846755
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg
Study: 32584425
Drug: Antiparasitic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparasitic treatment with albendazole
Study: 33493023
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of soybean protein (soy40)
Study: 33061822
Drug: Glucagon-like peptide-1
Normalized name: Glucagon-like peptide-1 (GLP-1) analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide-1 receptor agonist (GLP-1RA)
Study: 39323258
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine
Study: 32315295
Drug: Letrozole monotherapy
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole monotherapy in real-world cohort
Study: 33630863
Drug: Stockholm3 Model
Normalized name: Stockholm tar
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stockholm3 Model (S3M) test with reflex thresholds of 1.5 ng/mL
Study: 32338459
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test and reference drugs
Study: 34510814
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (leuprorelin acetate or goserelin acetate)
Study: 33285649
Drug: Active-unassisted robotic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-unassisted robotic therapy (n=8)
Study: 33285649
Drug: Active-assisted robotic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-assisted robotic therapy (n=6)
Study: 32247531
Drug: Insulin-dextrose infusion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-dextrose infusion for 120 minutes
Study: 32247531
Drug: Insulin-dextrose infusion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-dextrose infusion at 1.5 mU/kg/minute for 60 minutes
Study: 32247531
Drug: Insulin-dextrose infusion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-dextrose infusion at 0.5 mU/kg/minute for 60 minutes
Study: 33546963
Drug: Povidone iodine-based
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine-based rigid lens disinfecting solution
Study: 32804892
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with FMR and TFL
Study: 32506858
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution 0.2%
Study: 32598093
Drug: Adjunctive antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antidepressant treatment (late starters excluded)
Study: 35544051
Drug: Microneedle array
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microneedle array (MNA-10%) - 0.25 µg per patch, administered twice, 3 weeks apart
Study: 34578973
Drug: Caloric restriction
Normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caloric restriction with n-3 PUFA supplementation (1.8 g/day)
Study: 33713235
Drug: Low-dose ozone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ozone therapy
Study: 38654565
Drug: P2Y12 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P2Y12 inhibitor monotherapy
Study: 35691326
Drug: Short treatment
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short treatment group (500 mg intravenous imipenem-cilastatin four times a day for 72 hours)
Study: 35691326
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment group
Study: 34512522
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment plus acupuncture
Study: 34512522
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment plus sham acupuncture
Study: 32821737
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations
Study: 32195959
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with tamsulosin hydrochloride sustained-release capsule
Study: 32841941
Drug: Amoxicillin dosing
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin dosing regimens
Study: 35131532
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) vaginal gel
Study: 35131532
Drug: Polycarbophil vaginal
Normalized name: glycerin/min oil/polycarbophil VAGINAL GEL (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycarbophil vaginal (PCV) gel
Study: 33160908
Drug: Ibuprofen plus
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen plus oxycodone
Study: 36548927
Drug: Subcutaneous epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epcoritamab
Study: 32272260
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) 210 mL (18.6 mmol NO3‐)
Study: 33903052
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy
Study: 32702849
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment group
Study: 33108244
Drug: rhG-CSF combined
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhG-CSF combined with minimal-dose Dec (G-Dec group)
Study: 35984380
Drug: Nebulized Salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Salbutamol (5 mg) with Magnesium Sulphate (95 mg)
Study: 35984380
Drug: Nebulized Salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Salbutamol (5 mg) alone
Study: 35152531
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% minoxidil
Study: 34254405
Drug: Lanicemine (BHV-5500)
Normalized name: Lanicemine
DrugBank: Lanicemine (DB11889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanicemine (BHV-5500) 1.0 mg/ml (100 mg)
Study: 34762373
Drug: Conventional basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional basic treatment (control group)
Study: 34319514
Drug: Hydrogen gas
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen gas inhalation
Study: 35014069
Drug: ALKS 7119
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALKS 7119 (≥50 mg)
Study: 34653384
Drug: Poloxamer 407-based
Normalized name: POLOXAMER 407
DrugBank: Poloxamer 407 (DB11252)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poloxamer 407-based 0.75% ropivacaine hydrogel (22.5 mg)
Study: 33444565
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (60,000 IU monthly)
Study: 34836014
Drug: ASI +
Normalized name: ISOPROPYL ALCOHOL 43 mL in 60 mL TOPICAL GEL [ASI Chemicals Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASI + I (Inositol‐enhanced bonded arginine silicate) 1600 mg
Study: 33148502
Drug: RSA-biofeedback with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSA-biofeedback with treatment as usual (BFB + TAU)
Study: 35984478
Drug: POC-guided insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: POC-guided insulin adjustment
Study: 34037666
Drug: WIV04 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WIV04 vaccine (5 µg/dose; n=13,459)
Study: 34037666
Drug: HB02 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB02 vaccine (4 µg/dose; n=13,465)
Study: 39283627
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg
Study: 36074703
Drug: Ultrasound-assisted carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-assisted carbon nanoparticle suspension (CNS) mapping
Study: 34028623
Drug: All-inside tibial
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-inside tibial socket preparation (Group 2)
Study: 32762672
Drug: Low-dose exogenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exogenous surfactant (20 mg/kg)
Study: 32715866
Drug: Telehealth intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth intervention in pre-hospital and acute-care settings (n=11; 14.3%) for assessment and in rehabilitation and follow-up (n=61; 79.2%) for therapy delivery.
Study: 34878625
Drug: LY-CovMab 30
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CovMab 30 mg, 150 mg, 600 mg, 1200 mg, 2400 mg
Study: 34878625
Drug: LY-CovMab 150
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CovMab 150 mg
Study: 34878625
Drug: LY-CovMab 600
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY-CovMab 600 mg
Study: 32727558
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 IU oral drop daily for 5 days)
Study: 36008574
Drug: Yttrium-90 (Y90)
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90 (Y90) radioembolization with chemotherapy
Study: 37993169
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment
Study: 38082486
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg once daily
Study: 35997620
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment groups
Study: 34058036
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole
Study: 35963802
Drug: Olpasiran 75
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 75 mg (Non-Japanese group)
Study: 32484629
Drug: vehicle lotion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle lotion
Study: 33320381
Drug: Low-dose ticagrelor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ticagrelor (LD group, 45 mg twice daily)
Study: 34173969
Drug: UVA therapy
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA therapy
Study: 35983530
Drug: Conventional alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional alteplase and butalbital treatment
Study: 37217903
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by surgery
Study: 32270440
Drug: Imeglimin (IMEG)
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Imeglimin (DB12509)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Imeglimin (IMEG) 1500 mg twice daily with Sitagliptin (SITA) 100 mg once daily
Study: 33228458
Drug: Willingness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willingness to enroll in a clinical trial for a COVID-19 vaccine
Study: 35379019
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline Solution (SS)
Study: 36342475
Drug: Clopidogrel 75mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg once daily
Study: 32447856
Drug: Electroacupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture at Baihui (GV20) and Shuigou (GV26) points in addition to routine western medicine treatment.
Study: 32725861
Drug: Routine speech
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine speech therapy intervention
Study: 38221601
Drug: Parent-Child Interaction
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Child Interaction Therapy-Emotion Development (PCIT-ED)
Study: 32471808
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine treatment
Study: 34671996
Drug: Namodenoson 25
Normalized name: Namodenoson
DrugBank: Namodenoson (DB12885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namodenoson 25 mg b.d.
Study: 33044367
Drug: CUR +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CUR + FEN (500 mg·d)
Study: 32984946
Drug: Polaprezinc (PZ)
Normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polaprezinc (PZ) lozenge treatment
Study: 33355079
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen (Group B): omeprazole and amoxicillin for 5 days, followed by omeprazole, tinidazole, and levofloxacin for 5 days.
Study: 33393835
Drug: Galcanezumab 240
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 240 mg (EM from placebo-controlled trial)
Study: 33393835
Drug: Galcanezumab 240
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab 240 mg (CM)
Study: 35366920
Drug: L-carnitine (L-C)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine (L-C)
Study: 36865252
Drug: Diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics
Study: 33217362
Drug: Low-dose CoronaVac
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CoronaVac (3 μg per 0.5 mL)
Study: 33095777
Drug: Pre-operative home-based
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative home-based exercise therapy with one exercise
Study: 34626890
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo exposure therapy (IVET) for 5 weeks
Study: 93178847
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa therapy
Study: 33268476
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of NSAIDs
Study: 35633327
Drug: Protocol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol treatment with a course of hepatoprotector for one month
Study: 32320639
Drug: Prior history
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior history of second-line TB treatment
Study: 616330511
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7vPCV) in a 1-2-3 month schedule
Study: 36409491
Drug: Dual pathway
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual pathway inhibition (rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily)
Study: 32544914
Drug: Lutein plus
Normalized name: Lutein Plus with Zeaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein plus DHA group (LT/DHA-G)
Study: 32265253
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt‐PA)
Study: 33054890
Drug: Iron and
Normalized name: beef,iron and wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron and folic acid (IFA) - 60 mg/d Fe and 400 µg/d folic acid
Study: 37778226
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants
Study: 33077559
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) dressing, n=224
Study: 33272365
Drug: Atherogenic dyslipidemia
Normalized name: INVESTIGATIONAL DRUGS FOR DYSLIPIDEMIAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atherogenic dyslipidemia (triglycerides >150 mg/dl and HDL-C <40 mg/dl in men or <50 mg/dl in women)
Study: 35611568
Drug: Navigated central
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navigated central retinal laser and 2.0 mg aflibercept
Study: 34412103
Drug: Aflibercept monotherapy
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept monotherapy
Study: 33647718
Drug: GNAstV infection
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNAstV infection (0.5 mL GNAstV‐JSHA intramuscularly)
Study: 39171416
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual
Study: 34787858
Drug: PICC chemotherapy
Normalized name: STATLOCK PICC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICC chemotherapy
Study: 35101832
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus clausii UBBC07 (oral suspension of 2 billion spores twice daily for 30 days)
Study: 39325310
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms
Study: 34031695
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma containing neutralizing antibody to SARS-CoV-2
Study: 32173648
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication of risedronate sodium and raloxifene (SERM)
Study: 37442883
Drug: Oral Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Misoprostol
Study: 34586927
Drug: Traditional occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional occupational therapy (20 minutes)
Study: 32101207
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g RS4
Study: 36247927
Drug: Mazdutide 10
Normalized name: Mazdutide
DrugBank: Mazdutide (DB19099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazdutide 10 mg (2.5 mg weeks 1-4; 5 mg weeks 5-8; 7.5 mg weeks 9-12; 10 mg weeks 13-16)
Study: 35643873
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20 µg/day)
Study: 37640861
Drug: Natriuresis-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natriuresis-guided therapy